Results 61 to 70 of about 754,759 (237)
Bioethics of establishing a CHIM model for dengue vaccine development
International Journal of Infectious Diseases, 2019 Introduction: Controlled human infection models (CHIM) have been used in vaccine development to up-select and down-select potential vaccine candidates and to provide proof of vaccine efficacy, and have also been used as a basis for licensure of vaccines ...
Anuradha Rose, Amrita Sekhar
doaj +1 more source
Epidemiology (2012-2019) and costs (2009-2019) of dengue in Malaysia: a systematic literature review
International Journal of Infectious Diseases, 2022 Objectives: A systematic literature review was conducted to assess the epidemiology and economic burden of dengue in Malaysia. Methods: Embase, MEDLINE, Evidence-Based Reviews databases, and gray literature sources were searched for English and Malay ...
Sazaly AbuBakar +6 more
doaj +1 more source
Outlook for a dengue vaccine [PDF]
Clinical Microbiology and Infection, 2014 Dengue is an increasing medical problem in subtropical and tropical countries. The search for a safe and effective vaccine is complicated by the fact that there are four types of dengue virus and that, if a vaccine is live attenuated, it should be proven not to cause the life-threatening form of dengue, dengue haemorrhagic fever.
openaire +2 more sources
PLoS Neglected Tropical Diseases, 2013 BackgroundA face-to-face survey of 158 policymakers and other influential professionals was conducted in eight dengue-endemic countries in Asia (India, Sri Lanka, Thailand, Vietnam) and Latin America (Brazil, Colombia, Mexico, Nicaragua) to provide an ...
Don L Douglas +3 more
doaj +1 more source
Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses. [PDF]
PLoS Neglected Tropical Diseases, 2012 The major weaknesses of subunit vaccines are their low immunogenicity and poor efficacy. Adjuvants can help to overcome some of these inherent defects with subunit vaccines.
Chen-Yi Chiang +11 more
doaj +1 more source
Towards understanding of the replication and pathogenesis of dengue infection [PDF]
, 2007 Dengue is the most important human viral disease transmitted by arthropod vectors and over half of the world's population live in areas at risk of infection. Currently there is neither specific treatment nor vaccine to tackle this emerging disease. The
Umareddy, Indira
core +1 more source
Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore. [PDF]
PLoS Neglected Tropical Diseases, 2011 BACKGROUND: Dengue illness causes 50-100 million infections worldwide and threatens 2.5 billion people in the tropical and subtropical regions. Little is known about the disease burden and economic impact of dengue in higher resourced countries or the ...
Luis R Carrasco +10 more
doaj +1 more source
Cell, 2016 Denvaxia is the first licensed vaccine for the prevention of dengue. It is a live vaccine developed using recombinant DNA technology. The vaccine is given as three doses over the course of a year and has the potential to prevent hundreds of thousands of hospitalizations each year.
openaire +2 more sources
Vaccine, 2017 Since December 2015, the first dengue vaccine has been licensed in several Asian and Latin American countries for protection against disease from all four dengue virus serotypes.
O. Wichmann +9 more
semanticscholar +1 more source
Development of dengue vaccines [PDF]
, 2018 Background: Dengue virus (DENV) causes up to 390 million infections yearly, of which 96 million are clinically manifested. Approximately 500,000 people with severe dengue require hospitalization each year and there are at least 25,000 deaths among ...
Chit Laa Poh +3 more
core +1 more source